The Latest in Leukemia, Myelodysplasia, Transplantation

Minimal residual disease a powerful prognostic factor in AML

January 23, 2016

Leukemia, Myelodysplasia, Transplantation

Ofatumumab approved for extended treatment of CLL patients in complete or partial response

January 19, 2016

Leukemia, Myelodysplasia, Transplantation

Venetoclax gets 79% overall response rate in high-risk CLL

January 13, 2016

Leukemia, Myelodysplasia, Transplantation

Ibrutinib response durable at 1 year in CLL patients who relapsed after allogeneic stem cell transplants

January 13, 2016

Leukemia, Myelodysplasia, Transplantation

KIR2DL5B genotype predicts outcome in chronic phase–CML

January 7, 2016

Leukemia, Myelodysplasia, Transplantation

Cardiovascular risk assessment required with use of TKIs for CML

December 29, 2015

New agents effectively target CLL’s molecular Achilles

December 18, 2015

Leukemia, Myelodysplasia, Transplantation

Chemo quadruples risk for myeloid cancers

December 18, 2015

Leukemia, Myelodysplasia, Transplantation

More complete cytogenetic responses at 12 months with radotinib than imatinib

December 18, 2015

Leukemia, Myelodysplasia, Transplantation

Nilotinib safe, effective as first-line therapy for CML-CP patients age 65 and older

December 18, 2015

Leukemia, Myelodysplasia, Transplantation

Anti-BCL2, CD20 combo safe, effective in untreated CLL

December 17, 2015

Leukemia, Myelodysplasia, Transplantation

Academic hospitals offer better AML survival

December 15, 2015

ASH: Idelalisib plus standard therapy boosts survival in relapsed CLL

December 9, 2015

Leukemia, Myelodysplasia, Transplantation

VIDEO: High-intensity conditioning stands ground in MDS, AML

December 8, 2015

Leukemia, Myelodysplasia, Transplantation

Upfront idelalisib carries high risk for acute liver toxicity

December 8, 2015

Leukemia, Myelodysplasia, Transplantation